Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Regenicin's Sloan Ratio for the quarter that ended in Mar. 2023 was 0.00%.
As of Mar. 2023, Regenicin has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2023, Regenicin has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Regenicin Sloan Ratio % Related Terms
Regenicin Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Regenicin's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGIN vs NOVNQ, TMBRQ, RGRX: Sloan Ratio % Comparison
For the Biotechnology subindustry, Regenicin's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenicin Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regenicin's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Regenicin's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Regenicin's Sloan Ratio for the fiscal year that ended in Sep. 2022 is calculated as
Regenicin's Net Income for the trailing twelve months (TTM) ended in Mar. 2023 was -0.163 (Jun. 2022 ) + -0.155 (Sep. 2022 ) + -0.278 (Dec. 2022 ) + -0.336 (Mar. 2023 ) = $-0.93 Mil.
Regenicin's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2023 was -0.01 (Jun. 2022 ) + 0 (Sep. 2022 ) + -0.362 (Dec. 2022 ) + -0.328 (Mar. 2023 ) = $-0.70 Mil.
Regenicin's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2023 was 0 (Jun. 2022 ) + 0 (Sep. 2022 ) + 0 (Dec. 2022 ) + 0 (Mar. 2023 ) = $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenicin (RGIN) has a Sloan Ratio % of 0.00% as of Mar. 2023. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Regenicin and its competitors.
Is Regenicin's Sloan Ratio % too high?
Regenicin's current Sloan Ratio % is 0.00%.
How does Regenicin's Sloan Ratio % compare to NOVNQ and TMBRQ?
Regenicin's Sloan Ratio % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Regenicin and its competitors. Regenicin's current Sloan Ratio % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenicin stock overvalued right now?
Regenicin (RGIN) has a current Sloan Ratio % of 0.00%. The current Sloan Ratio % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Regenicin (RGIN), the current Sloan Ratio % is 0.00% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGIN has been successfully added to your 
